TrialJNCI cancer spectrum2026

Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.

Pamela J Goodwin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.